	Application	No	Applicant(s)					
	Application No.		Applicant(s)					
Notice of Allowability	09/697,863		PYPE ET AL.					
	Examiner		Art Unit					
	Samuel W L	iu	1653					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.								
1. This communication is responsive to <u>papers filed 8-26-03</u> ,	3-24-03, 11-4-	<u>02 and 5-8-01</u> .						
2. The allowed claim(s) is/are <u>1,5,6,19,24 and 26-28</u> .								
3. The drawings filed on <u>27 October 2000</u> are accepted by the								
 4. Acknowledgment is made of a claim for foreign priority und a) All b) Some* c) None of the: 	der 35 U.S.C. §	} 119(a)-(d) or (f).						
 Certified copies of the priority documents have 	e been receive	d.						
Certified copies of the priority documents have								
3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).								
* Certified copies not received:								
5. Acknowledgment is made of a claim for domestic priority u	ınder 35 U.S.C	. § 119(e) (to a provisi	onal application).					
(a) The translation of the foreign language provisional a								
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.								
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.								
8. CORRECTED DRAWINGS must be submitted.			Y					
(a) including changes required by the Notice of Draftspel	rson's Patent D	rawing Review (PTO	-948) attached					
1) hereto or 2) to Paper No		•						
(b) ☐ including changes required by the proposed drawing	correction filed	L, which has be	een approved by the	Examiner.				
(c) ☐ including changes required by the attached Examine								
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet.								
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.								
Attachment(s)								
 1 Notice of References Cited (PTO-892) 3 Notice of Draftperson's Patent Drawing Review (PTO-948) 5 Information Disclosure Statements (PTO-1449), Paper No 7 Examiner's Comment Regarding Requirement for Deposit of Biological Material 	·	2☐ Notice of Informa 4☑ Interview Summ 6☑ Examiner's Ame 8☐ Examiner's State 9☐ Other	ary (PTO-413), Pape indment/Comment	er No. <u>4/23/0</u> 3.				



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

NOTICE OF ALLOWANCE AND FEE(S) DUE

24247

10/23/2003

801-531-9168

TRASK BRITT P.O. BOX 2550 SALT LAKE CITY, UT 84110

RECEIVED

OCT 2 7 2003

Trask Britt

EXAMINER LTU, SAMUEL W

ART UNIT PAPER NUMBER 1653

DATE MAILED: 10/23/2003

APPLICATION NO,	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/697,863	10/27/2000	Stefan M C Pype	4555US	7540

TITLE OF INVENTION: CD40-INTERACTING AND TRAF-INTERACTING PROTEINS

APPLN, TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$665	\$0	\$665	01/23/2004

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown abovę,

B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.

Applicant claims SMALL ENTITY status. Sec 37 CFR 1.27,

II. PART B - FEE(\$) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

Page 1 of 4

PTOL-85 (Rev. 10/03) Approved for use through 04/30/2004,

Application/Control Number: 09/697,863

Art Unit: 1653

DETAILED ACTION

This Office action is in response to (i) applicants' amendments filed 26 August 2003 which adds claims 26-28, cancels claims 3, 20, 23 and 25 and amends claims 26-28, (ii) applicants' amendment filed 24 March 2003 which amends claims 1, 6, 19 and 20, (iii) applicants' amendment filed 4 November 2002 which cancels claims 8-10, 12-18 and 22, adds claims 23-25, and amends claims 1, 3, 5-6 and 20, and (iv) preliminary amendment filed 8 May 2001 which cancels claims 2, 4, 7, 11 and 21, adds claim 22, and amends claims 1, 3, 5-6, 8-10 and 12-19. The amendments indicated above have been entered.

The pending claims 1, 5-6, 19, 24 and 26-28 are therefore examined in this Office action.

EXAMINER'S AMENDMENT

An Examiner's Amendment to the record appears below. Should the change and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no latter than payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Bretton L. Crockett on September 23. 2003.

Amendments to the specification:

In page 3, line 23, change "TNF-RI, TNF-RII" to "TNF receptor type I (TNF-RI), TNF receptor type II (TNF-RII)".

In page 12, lines 10-11, change "CaM = calcium calmodulin binding region" to "CaM stands for calcium calmodulin".

In page 18, line 19, change "X-gal" to "5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal)".

Amendments to the claims:

Application/Control Number: 09/697,863

Art Unit: 1653

In claim 1 (*five times amendment*), change "including" to "and", before "amino acids in length" add "consecutive", and change "and" to "which is" before "able to...".

In claim 5 (four times amendment), change "is a fragment, said fragment comprising" to "comprises".

In claim 6 (five times amendment), change "is a fragment comprising" to "comprises".

In claim 19 ((four times amendment), delete "or a functional fragment thereof of at least 10 amino acids in length and able to form said complex".

Conclusion: claims 1, 5-6, 19, 24 and 26-28 are allowable over the art of record.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Samuel Wei Liu, Ph.D. whose telephone number is (703) 306-3483. The Examiner can normally be reached daily except alternate Fridays from 8:30 A.M. to 5:30 P.M. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Christopher Low, can be reached at (703) 308-2329. The official fax phone number for Technology Center 1600 is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Karen Coe have Carlon Red.

Samuel W. Liu, Ph.D.

September 23, 2003

KAREN COCHRANE CARLSON, PH.D. PRIMARY EXAMINER